Aurealis Therapeutics Information

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapies, based on genetically modified safe lactic acid bacteria, address unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammatory diseases. After successfully completing Phase 1 and Phase 2 clinical studies in Diabetic Foot Ulcer (DFU) with our lead asset AUP-16, we're actively preparing a global DFU Phase 3 study. Other indications will follow In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.